Ghana is reaffirming its commitment to becoming a leading pharmaceutical and biotechnology hub in Africa, leveraging President John Dramani Mahama’s Accra Reset initiative to transform the country’s health sector into a key economic driver.
The strategy is designed to build a robust pharmaceutical system that serves the Ghanaian people, while international partners, including India, are already showing interest in supporting or investing in the sector.
President Mahama has articulated a vision that positions health not only as a social service but as a strategic economic sector capable of generating jobs, driving industrial growth, and strengthening public health resilience across the continent. He emphasized:
“What if we produced our own vaccines and our own medicines with our own technology? This is the Accra Reset vision. It is not a talk show. It is not a declaration. It is a practical blueprint for how countries can work together to build real sovereignty, the kind that can be measured in jobs created, children in school, children vaccinated, and young people thriving.”
Central to this vision is a push for local manufacturing of vaccines, medicines, and cutting-edge health technologies, reducing dependency on imports and positioning Ghana as a gateway for pharmaceutical manufacturing in West Africa and beyond.
Minister of Foreign Affairs Samuel Okudzeto Ablakwa highlighted the global significance of Ghana’s leadership
“President Mahama continues to offer inspirational global leadership as Ghana’s stature in the comity of nations soars higher and brighter. We shall keep working hard to uplift the image of our country as we co-create solutions with willing partners to resolve the challenges afflicting the people we serve.”
Ghana is actively building bilateral and multilateral partnerships to create an enabling environment for pharmaceutical companies to invest, co‑innovate, and co‑manufacture locally. The country’s political stability, market access, and investor protection frameworks make it an attractive destination for Indian and other international investors looking to expand their footprint in Africa.
Some initiatives have already made tangible progress, with technology transfer agreements underway and local production of vaccines and other health products beginning. These developments highlight Ghana’s potential to become a regional hub for vaccine and biologics manufacturing, serving both domestic demand and export markets across West Africa.
Ghana’s strategic focus on health sovereignty may deliver multiple economic benefits, including reducing dependence on imported medicines, lowering healthcare costs, creating high-skilled jobs, and stimulating growth in logistics, research, and regulatory services. With Africa importing the majority of its medicines and active pharmaceutical ingredients, Ghana’s commitment to local production may position the country to address a critical regional gap while driving export-oriented industrialisation.
